SILO Pharma (SILO) Gains 53%
For Now, Volatility Remains and the Traders, Seem to be Having the Most Fun.
Silo Pharma Gains 53%...
Psycheceutical’s (BWVI) NeuroDirect™ Ketamine can Help Alleviate Headaches and Migraines Within Minutes, With no...
Photo MAPS Founder Rick Doblin visits Psycheceutical's Chief Visionary Officer Mike 'Zappy' Zapolin, CEO Chad Harman at the company's lab and tests...
Coming This Monday..
Microdose's Wonderland: Miami Conference to be held at the Adrienne Arsht Center for the Performing Arts in Miami, FL on November...
That’s it. $225 Million Raised by Atai (ATAI) Gets us Interested in the Psychedelics...
Redefining how the world approaches, prevents, and heals mental health disorders.
LIVE QUOTE
Ehave (EHVVF) Looks to Power the Psychedelics Revolution
Mental illness will cost the global economy $16 trillion by 2030 due to early-onset and lost productivity, with an estimated 12 billion working days...
Advances in Psychedelics can Change Investors’ Minds
Original article(s) on EXBulletin and Financial Times
The science behind this subject has become mainstream in recent years. Excellent...
The Psychedelic Revolution Is Coming. Psychiatry May Never Be the Same (New York Times).
Summary: MAPS is featured in an article on the front page of today's edition of The New York Times!
Huge News at Ehave Inc.(EHVVF), our Favorite Psychedelic.
We just finished compiling the 2021 Psychedelic Investor Guide and reviewed 44 companies - in all shapes and sizes. Excluding Johnson &...
Topical PTSD Drug Poised for Human Trials.
In a press release issued on February 15, Psycheceutical Bioscience (BWVI), in partnership with iNGENū, a contract research organization in the cannabinoid...
Adding Silo Pharma (SILO) $3.50 to Watch List.
Look What We Found!
We launched the Psychedelic Stock Review a little more than a year ago and decided...